323 related articles for article (PubMed ID: 22926712)
21. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
22. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas.
Rufini V; Treglia G; Perotti G; Giordano A
Hormones (Athens); 2013; 12(1):58-68. PubMed ID: 23624132
[TBL] [Abstract][Full Text] [Related]
23. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
24. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
25. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Taïeb D; Pacak K
Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723
[TBL] [Abstract][Full Text] [Related]
26. New imaging approaches to phaeochromocytomas and paragangliomas.
Dullaart RP; van der Horst-Schrivers AN; Koopmans KP
Clin Endocrinol (Oxf); 2010 Apr; 72(4):568-9; author reply 569. PubMed ID: 19769625
[No Abstract] [Full Text] [Related]
27. Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery.
Nockel P; El Lakis M; Gaitanidis A; Merkel R; Patel D; Nilubol N; Prodanov T; Pacak K; Kebebew E
Ann Surg; 2019 Apr; 269(4):741-747. PubMed ID: 29334561
[TBL] [Abstract][Full Text] [Related]
28. Current trends in functional imaging of pheochromocytomas and paragangliomas.
Shulkin BL; Ilias I; Sisson JC; Pacak K
Ann N Y Acad Sci; 2006 Aug; 1073():374-82. PubMed ID: 17102106
[TBL] [Abstract][Full Text] [Related]
29. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
[TBL] [Abstract][Full Text] [Related]
30.
Kan Y; Zhang S; Wang W; Liu J; Yang J; Wang Z
Acta Radiol; 2018 Dec; 59(12):1466-1474. PubMed ID: 29566550
[TBL] [Abstract][Full Text] [Related]
31. The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.
Kong G; Schenberg T; Yates CJ; Trainer A; Sachithanandan N; Iravani A; Ravi Kumar A; Hofman MS; Akhurst T; Michael M; Hicks RJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5091-5099. PubMed ID: 30977831
[TBL] [Abstract][Full Text] [Related]
32. First Experience Using
Kessler L; Schlitter AM; Krönke M; von Werder A; Tauber R; Maurer T; Robinson S; Orlandi C; Herz M; Yousefi BH; Nekolla SG; Schwaiger M; Eiber M; Rischpler C
J Nucl Med; 2021 Apr; 62(4):479-485. PubMed ID: 32859709
[TBL] [Abstract][Full Text] [Related]
33. Diuretic 68Ga DOTANOC PET/CT in imaging of bladder paraganglioma.
Dhull VS; Karunanithi S; Arora S; Jain TK; Kumar R
Clin Nucl Med; 2014 Oct; 39(10):915-6. PubMed ID: 24566403
[TBL] [Abstract][Full Text] [Related]
34. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
35. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
[TBL] [Abstract][Full Text] [Related]
36. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
[TBL] [Abstract][Full Text] [Related]
37. Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease.
Kroiss AS
Wien Med Wochenschr; 2019 Feb; 169(1-2):25-32. PubMed ID: 30182289
[TBL] [Abstract][Full Text] [Related]
38. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma?
Taïeb D; Sebag F; Hubbard JG; Mundler O; Henry JF; Conte-Devolx B
Clin Endocrinol (Oxf); 2004 Jul; 61(1):102-8. PubMed ID: 15212651
[TBL] [Abstract][Full Text] [Related]
39. Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma.
Nakamoto R; Nakamoto Y; Ishimori T; Togashi K
Clin Nucl Med; 2016 Nov; 41(11):e465-e472. PubMed ID: 27607159
[TBL] [Abstract][Full Text] [Related]
40. From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.
Patel HV; Srivastava A; Becker MD; Beninato T; Laird AM; Singer EA
Curr Urol Rep; 2021 Jan; 22(1):2. PubMed ID: 33403502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
